Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients

Inclusion Criteria: * Participants must be with biopsy-confirmed diagnosis of multiple myeloma before the first mobilization, in first or second complete or partial remission * The patient is eligible for autologous transplantation and treatment with an autologous peripheral Hematopoietic stem cell (HSC) transplant is planned * Eastern Cooperative Oncology Group performance status of 0 or 1 * Recovered from all acute toxic effects of prior chemotherapy or other cancer treatment * Has an actual body weight \<175% of their ideal body weight (IBW) * In agreement to use an approved form of contraception if of childbearing potential Exclusion Criteria: * If they had a comorbid condition which, in the view of the investigators, rendered the patient at high risk from treatment complications * Active brain metastases or myelomatous meningitis * Abnormal Electrocardiogram (ECG) with clinically significant rhythm disturbance (ventricular arrhythmias), or other conduction abnormality in the last year that in the opinion of the investigator warrants exclusion of the subject from the trial. * Active infection requiring antibiotic treatment * Fever (temperature \> 38°C) * Positive pregnancy test in female patients * Lactating females * Had prior autologous or allogeneic transplantation * Received bone-seeking radionuclides * Received \>6 cycles of induction therapy with lenalidomide * Received \>2 cycles of alkylating agent combinations * Received more than 2 regimens of alkylating agen…